KEY TAKEAWAYS
- The study aimed to investigate Nrf2-ARE genes in relation to CRF in postmenopausal women with early-stage BC.
- The study concluded that biomarkers based on Nrf2-ARE genes could potentially identify women at increased risk for severe CRF.
To explore genes in the nuclear factor E2-related factor 2 antioxidative response elements (Nrf2-ARE) signaling pathway using a multiomics approach for associations with variability of cancer-related fatigue (CRF) in postmenopausal women with early-stage hormone receptor-positive breast cancer (BC). They recruited postmenopausal women (N = 116) with early-stage hormone receptor-positive BC from western Pennsylvania.
Tara S. Davis and the team aimed to assess the role of Nrf2-ARE genes in understanding the variability of CRF in this cohort.
They performed an inclusive analysis of candidate genes from the Nrf2-ARE pathway to investigate their associations with the occurrence and severity of CRF. Associations were evaluated using logistic regression for occurrence and linear regression for severity, focusing on postmenopausal women with early-stage hormone receptor-positive BC from western Pennsylvania.
The rs2706110 TT genotype in NFE2L2, it was associated with a 3.5-fold increase in odds of CRF occurrence. Additionally, the cytosine-phosphate-guanine (CpG) site cg22820568 in PRDX1 showed associations with both CRF occurrence and severity.
The study concluded that biomarkers derived from Nrf2-ARE genes have the potential to identify women at heightened risk for severe CRF, facilitating the development of precise interventions.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/38950096/
Davis T.S., Koleck T.A., Rosenzweig M.Q., et al. (2024). “Association Between Genes in the Nuclear Factor E2-Related Factor 2 Antioxidative Response Elements Pathway and Cancer-Related Fatigue in Women With Early-Stage Breast Cancer.” Oncol Nurs Forum. 2024 Jun 14;51(4):404-416. doi: 10.1188/24.ONF.404-416. PMID: 38950096.
